Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discovery of a Non-Nucleoside SETD2 Methyltransferase Inhibitor against Acute Myeloid Leukemia.

International journal of molecular sciences - 17 Sept 2021

Bajusz Dávid, Bognár Zsolt, Ebner Jessica, Grebien Florian, Keserű György M

Abstract excerpt

Histone methyltransferases (HMTs) have attracted considerable attention as potential targets for pharmaceutical intervention in various malignant diseases. These enzymes are known for introducing methyl marks at specific locations of histone proteins, creating a complex system that regulates epigenetic control of gene expression and cell differentiation. Here, we describe the identification of first-generation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve
Share to Chemistry, Pharmaceutical

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Databases, Factual

Share to Drug Design

Share to Drug Discovery

Share to Histone-Lysine N-Methyltransferase

Share to Inhibitory Concentration 50

Share to Pharmaceutical Preparations

Source

Open in PubMed Open full text

Identifiers

PMID: 34576219
DOI: 10.3390/ijms221810055
PMCID: PMC8471172

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discovery of a Non-Nucleoside SETD2 Methyltransferase Inhibitor against Acute Myeloid Leukemia.PMID 34576219Read ↗

Downregulation of the histone methyltransferase SETD2 promotes imatinib resistance in chronic myeloid leukaemia cellsSemantic proximity Read ↗

The SETD2 L1609P mutation found in leukemia disrupts methyltransferase activity and reduces histone H3K36 trimethylation.Semantic proximity Read ↗

Integrated Computational and Functional Screening Identifies G9a Inhibitors for SETD2-mutant Leukemia.Semantic proximity Read ↗

Roles of SETD2 in Leukemia—Transcription, DNA-Damage, and BeyondSemantic proximity Read ↗

SETD2 Deficiency Confers Sensitivity to Dual Inhibition of DNA Methylation and PARP in Kidney Cancer.Semantic proximity Read ↗

SETting the Stage for Cancer Development: SETD2 and the Consequences of Lost Methylation.Semantic proximity Read ↗

<i>In silico</i> Exploration Natural Compounds for the Discovery of Novel DNMT3A Inhibitors as Potential Therapeutic Agents for Acute Myeloid LeukemiaSemantic proximity Read ↗

Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia.Semantic proximity Read ↗

Identification of functional cooperative mutations of SETD2 in human acute leukemia.Semantic proximity Read ↗

DNA methyltransferase inhibitors in cancer: a chemical and therapeutic patent overview and selected clinical studiesSemantic proximity Read ↗

DNA Methylation–Targeted DrugsSemantic proximity Read ↗

Molecular basis for oncohistone H3 recognition by SETD2 methyltransferase.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.